home
about us
our story
OUR MISSION
OUR VALUES
OUR PARTNERS
OUR SCIENTIFIC CO-FOUNDERS
OUR MANAGEMENT
OUR BOARD
TALENTS
science
F prau.
in Iflammatory Bowel Diseases
F prau.
in Cancer
MANUFACTURING LIVE BIOThERAPEUTICS
pipeline
Overview
Patients
Exl01 in Crohn's diseases
Exl01 in Cancer Immunotherapy
newsroom
PUBLICATIONS
contact
menu
about us
about us
Our story
Our mission
Our values
Our partners
Our Scientific Co-founders
Our management
Our board
Talents
science
science
Exl01
Crohn's Disease
Faecalibacterium Prausnitzii
in Inflammatory Bowel Diseases
Faecalibacterium Prausnitzii
immuno-oncology
Faecalibacterium Prausnitzii
in Recurrent
Clostridium difficile
Infections
Tryptophan metabolism
Manufacturing Live Biotherapeutics
pipeline
pipeline
OVERVIEW
Patients
EXL01 in Crohn’s Disease
EXL01 in Cancer Immunotherapy
EXL01 in Immuno-Oncology
EXL01 in recurrent
Clostridium difficile
infections
EXL02
EXL03
Regulatory Expertise
Intellectual Property
newsroom
newsroom
Corporate Presentation
Publications
News
Upcoming Events
contact
Paris Biotech Santé
Sep 25, 2017
Exeliom Biosciences joins Paris Biotech Santé Incubator
Back to news
Mar 21, 2023
Exeliom Biosciences Announces First Patient Enrolled in Phase 1 Study for the Maintenance in Remission in Adult Patients With Mild to Moderate Crohn's Disease
Explore
H2020 Accelerator Program Live Biotherapeutics Manufacturing
Aug 3, 2020
Exeliom Biosciences has been awarded a 2.5M€ H2020 Accelerator Program Grant from the European Innovation Council
Explore
Apr 27, 2023
SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism
Explore
contact
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
